IS8266A - Breytt mennsk IGF-1R mótefni - Google Patents

Breytt mennsk IGF-1R mótefni

Info

Publication number: IS8266A
Authority: IS; Iceland
Prior art keywords: antibody; modified human; human igf; igf; modified
Prior art date: 2003-08-13

Application number

IS8266A

Other languages

English (en)

Inventor

David Cohen Bruce

Bedian Vahe

Original Assignee

Pfizer Products Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-08-13

Filing date

2006-01-26

Publication date

2006-01-26

2006-01-26 Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.

2006-01-26 Publication of IS8266A publication Critical patent/IS8266A/is

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Heart & Thoracic Surgery (AREA)
Transplantation (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Hematology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

IS8266A 2003-08-13 2006-01-26 Breytt mennsk IGF-1R mótefni IS8266A (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US49520003P	2003-08-13	2003-08-13
PCT/IB2004/002555 WO2005016967A2 (en)	2003-08-13	2004-08-03	Modified human igf-1r antibodies

Publications (1)

Publication Number	Publication Date
IS8266A true IS8266A (is)	2006-01-26

Family

ID=34193291

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS8266A IS8266A (is)	2003-08-13	2006-01-26	Breytt mennsk IGF-1R mótefni

Country Status (37)

Country	Link
US (2)	US7371378B2 (is)
EP (1)	EP1656391B1 (is)
JP (1)	JP4638870B2 (is)
KR (1)	KR100825156B1 (is)
CN (1)	CN1835975B (is)
AP (1)	AP2006003510A0 (is)
AR (1)	AR045247A1 (is)
AT (1)	ATE484525T1 (is)
AU (1)	AU2004265152A1 (is)
BR (1)	BRPI0413466A (is)
CA (1)	CA2535071A1 (is)
CL (1)	CL2004002035A1 (is)
CR (1)	CR8233A (is)
DE (1)	DE602004029581D1 (is)
DK (1)	DK1656391T3 (is)
EA (1)	EA200600234A1 (is)
EC (1)	ECSP066359A (is)
ES (1)	ES2351395T3 (is)
GT (1)	GT200400158A (is)
IL (1)	IL173273A (is)
IS (1)	IS8266A (is)
MA (1)	MA27988A1 (is)
MX (1)	MXPA06001634A (is)
NL (1)	NL1026829C2 (is)
NO (1)	NO20060542L (is)
OA (1)	OA13234A (is)
PA (1)	PA8608801A1 (is)
PE (1)	PE20050339A1 (is)
PL (1)	PL1656391T3 (is)
PT (1)	PT1656391E (is)
RS (1)	RS20060099A (is)
TN (1)	TNSN06050A1 (is)
TW (1)	TWI294915B (is)
UA (1)	UA85058C2 (is)
UY (1)	UY28464A1 (is)
WO (1)	WO2005016967A2 (is)
ZA (1)	ZA200601231B (is)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2796468A2 (en)	2001-01-05	2014-10-29	Pfizer Inc	Antibodies to insulin-like growth factor I receptor
NZ571508A (en)	2002-05-24	2010-05-28	Schering Corp	Neutralizing human anti-IGFR antibody
WO2005016970A2 (en) *	2003-05-01	2005-02-24	Imclone Systems Incorporated	Fully human antibodies directed against the human insulin-like growth factor-1 receptor
DE602004029581D1 (de) *	2003-08-13	2010-11-25	Pfizer Prod Inc	Modifizierte humane igf-1r antikörper
US7326567B2 (en)	2003-11-12	2008-02-05	Schering Corporation	Plasmid system for multigene expression
TW200526684A (en)	2003-11-21	2005-08-16	Schering Corp	Anti-IGFR1 antibody therapeutic combinations
WO2006008639A1 (en)	2004-07-16	2006-01-26	Pfizer Products Inc.	Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
FR2873699B1 (fr) *	2004-07-29	2009-08-21	Pierre Fabre Medicament Sa	Nouveaux anticorps anti igf ir rt leurs utilisations
MX2007006640A (es)	2004-12-03	2007-06-19	Schering Corp	Biomarcadores para la preseleccion de pacientes para la terapia con anti-receptor 1 del factor de crecimiento similar a la insulina.
MY146381A (en)	2004-12-22	2012-08-15	Amgen Inc	Compositions and methods relating relating to anti-igf-1 receptor antibodies
GB0500417D0 (en) *	2005-01-10	2005-02-16	Cambridge Antibody Tech	Method of mutagenesis
AU2006236637B2 (en) *	2005-04-15	2012-09-06	Merck Sharp & Dohme Corp.	Methods and compositions for treating or preventing cancer
CN101287761A (zh) *	2005-06-15	2008-10-15	先灵公司	抗-igf1r抗体制剂
PT2100618E (pt)	2005-06-17	2014-04-07	Philadelphia Health & Educatio	Um anticorpo anti-pdgfr-alfa para o tratamento de cancro ósseo metastático
FR2888850B1 (fr) *	2005-07-22	2013-01-11	Pf Medicament	Nouveaux anticorps anti-igf-ir et leurs applications
AU2007212447B2 (en) *	2006-02-03	2013-02-21	Imclone Llc	IGF-IR antagonists as adjuvants for treatment of prostate cancer
AU2007229554A1 (en) *	2006-03-28	2007-10-04	F. Hoffmann-La Roche Ag	Anti-IGF-1R human monoclonal antibody formulation
US7846724B2 (en)	2006-04-11	2010-12-07	Hoffmann-La Roche Inc.	Method for selecting CHO cell for production of glycosylated antibodies
CA2653745C (en)	2006-06-02	2013-11-19	Pfizer Products Inc.	Circulating tumor cell assay
WO2008079849A2 (en) *	2006-12-22	2008-07-03	Genentech, Inc.	Antibodies to insulin-like growth factor receptor
GB0702888D0 (en) *	2007-02-14	2007-03-28	Glaxo Group Ltd	Novel Antibodies
AU2012203443B2 (en) *	2007-03-02	2014-03-06	Amgen Inc.	Methods and compositions for treating tumor diseases
WO2008108986A2 (en) *	2007-03-02	2008-09-12	Amgen Inc.	Methods and compositions for treating tumor diseases
WO2008116103A2 (en) *	2007-03-22	2008-09-25	Imclone Llc	Stable antibody formulations
US8492328B2 (en)	2007-05-17	2013-07-23	Bristol-Myers Squibb Company	Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
CA2709029A1 (en)	2007-12-21	2009-07-02	Bianca Eser	Stability testing of antibodies
CA2718918A1 (en) *	2008-03-25	2009-11-26	Schering Corporation	Methods for treating or preventing colorectal cancer
US20110129456A1 (en) *	2008-05-05	2011-06-02	Yaolin Wang	Sequential Administration of Chemotherapeutic Agents for Treatment of Cancer
CA2742861A1 (en) *	2008-11-06	2010-05-14	Alexion Pharmaceuticals, Inc.	Engineered antibodies with reduced immunogenicity and methods of making
EP2400985A2 (en)	2009-02-25	2012-01-04	OSI Pharmaceuticals, LLC	Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor
EP2236139A1 (en)	2009-03-31	2010-10-06	F. Hoffmann-La Roche AG	Combination therapy of erlotinib with an anti-IGF-1R antibody, which does not inhibit binding of insulin to the insulin receptor
WO2010146059A2 (en)	2009-06-16	2010-12-23	F. Hoffmann-La Roche Ag	Biomarkers for igf-1r inhibitor therapy
TWI513465B (zh)	2009-06-25	2015-12-21	Regeneron Pharma	以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
EP4406615A3 (en)	2009-10-26	2024-12-11	F. Hoffmann-La Roche AG	Method for the production of a glycosylated immunoglobulin
WO2011053779A2 (en)	2009-10-30	2011-05-05	Bristol-Myers Squibb Company	Methods for treating cancer in patients having igf-1r inhibitor resistance
AU2014262201B2 (en) *	2009-12-23	2016-09-15	Novartis Ag	Method for decreasing immunogenicity
KR101758703B1 (ko)	2009-12-23	2017-07-18	에스바테크 - 어 노바티스 컴파니 엘엘씨	면역원성의 감소 방법
US20110200595A1 (en)	2010-02-18	2011-08-18	Roche Glycart	TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
WO2011161119A1 (en)	2010-06-22	2011-12-29	F. Hoffmann-La Roche Ag	Antibodies against insulin-like growth factor i receptor and uses thereof
PE20130643A1 (es)	2010-07-12	2013-06-07	Covx Technologies Ireland Ltd	Conjugados de anticuerpos multifuncionales
US20140037642A1 (en)	2011-02-02	2014-02-06	Amgen Inc.	Methods and compositions relating to inhibition of igf-1r
US20140178368A1 (en)	2011-04-19	2014-06-26	Leslie Lynne SHARP	Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
US20140309229A1 (en)	2011-10-13	2014-10-16	Bristol-Myers Squibb Company	Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
EP2802355B1 (en) *	2012-01-09	2018-09-05	CovX Technologies Ireland Limited	Mutant antibodies and conjugation thereof
EP2631653A1 (en)	2012-02-24	2013-08-28	Charité - Universitätsmedizin Berlin	Identification of modulators of binding properties of antibodies reactive with a member of the insulin receptor family
WO2013152252A1 (en)	2012-04-06	2013-10-10	OSI Pharmaceuticals, LLC	Combination anti-cancer therapy
KR20150082367A (ko) *	2012-11-06	2015-07-15	메디뮨 엘엘씨	항슈도모나스 ｐｓｌ 및 ｐｃｒｖ 결합 분자를 이용한 병용 요법
US20160068613A1 (en)	2013-04-29	2016-03-10	Hoffmann-La Roche Inc.	Fc-receptor binding modified asymmetric antibodies and methods of use
EP3628685A1 (en)	2013-04-29	2020-04-01	F. Hoffmann-La Roche AG	Human fcrn-binding modified antibodies and methods of use
CN103319598B (zh) *	2013-05-13	2014-10-22	杭州德同生物技术有限公司	抗胰岛素样生长因子-1受体抗体及其编码基因和应用
CA2932364A1 (en)	2014-01-15	2015-07-23	F. Hoffmann-La Roche Ag	Fc-region variants with improved protein a-binding
KR102014066B1 (ko)	2017-01-06	2019-10-21	에이비엘바이오 주식회사	항 α-syn 항체 및 그 용도
IL272227B2 (en) *	2017-07-27	2025-09-01	iTeos Belgium SA	Anti-tigit antibodies
BR112020011875A2 (pt)	2017-12-14	2020-11-24	Abl Bio Inc.	anticorpo biespecífico ao a-syn/igf1r e uso do mesmo

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6054561A (en)	1984-02-08	2000-04-25	Chiron Corporation	Antigen-binding sites of antibody molecules specific for cancer antigens
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
US6657103B1 (en)	1990-01-12	2003-12-02	Abgenix, Inc.	Human antibodies derived from immunized xenomice
GB9203459D0 (en) *	1992-02-19	1992-04-08	Scotgen Ltd	Antibodies with germ-line variable regions
US5863949A (en)	1995-03-08	1999-01-26	Pfizer Inc	Arylsulfonylamino hydroxamic acid derivatives
DK0821671T3 (da)	1995-04-20	2001-04-23	Pfizer	Arylsulfonylhydroxamsyrederivater som MMP- og TNF-inhibitorer
EP0822830B1 (en)	1995-04-27	2008-04-02	Amgen Fremont Inc.	Human anti-IL-8 antibodies, derived from immunized xenomice
IL118626A0 (en)	1996-06-11	1996-10-16	Xtl Biopharmaceuticals Limited	Anti HBV antibody
HUP9903014A3 (en)	1996-07-18	2000-08-28	Pfizer	Phosphinate derivatives having matrix metalloprotease inhibitor effect and medicaments containing the same
US6153609A (en)	1996-08-23	2000-11-28	Pfizer Inc	Arylsulfonylamino hydroxamic acid derivatives
JP2002515511A (ja)	1998-05-15	2002-05-28	イムクローンシステムズインコーポレイティド	放射線及び成長因子レセプター・チロシン・キナーゼのインヒビターを使用するヒト腫瘍の治療
EE05627B1 (et) *	1998-12-23	2013-02-15	Pfizer Inc.	CTLA-4 vastased inimese monoklonaalsed antikehad
CA2796140A1 (en)	1999-03-25	2000-09-28	Jochen Salfeld	Human antibodies that bind human il-12 and methods for producing
ES1042735Y (es)	1999-04-07	2000-02-16	Martinez Fernando Martinez	Vehiculo tripersonal de accionamiento a pedales.
US20030165502A1 (en)	2000-06-13	2003-09-04	City Of Hope	Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
DE10033869C2 (de)	2000-07-12	2003-07-31	Karlsruhe Forschzent	HTS-Kryomagnet und Aufmagnetisierungsverfahren
EP2796468A2 (en) *	2001-01-05	2014-10-29	Pfizer Inc	Antibodies to insulin-like growth factor I receptor
CN100488563C (zh)	2001-02-19	2009-05-20	默克专利有限公司	免疫原性降低的经修饰抗egfr抗体
EP1806364B1 (fr)	2002-01-18	2013-07-31	Pierre Fabre Medicament	Nouveaux anticorps anti-igf-ir et leurs applications
WO2003093317A1 (en)	2002-04-30	2003-11-13	Kyowa Hakko Kogyo Co., Ltd.	Antibody to human insulin-like growth factor
NZ571508A (en)	2002-05-24	2010-05-28	Schering Corp	Neutralizing human anti-IGFR antibody
GB0212303D0 (en)	2002-05-28	2002-07-10	Isis Innovation	Molecular targetting of IGF-1 receptor
US7538195B2 (en)	2002-06-14	2009-05-26	Immunogen Inc.	Anti-IGF-I receptor antibody
CA2514231A1 (en)	2003-02-13	2004-08-26	Pfizer Products Inc.	Uses of anti-insulin-like growth factor i receptor antibodies
CA2518980A1 (en)	2003-03-14	2004-09-30	Pharmacia Corporation	Antibodies to igf-i receptor for the treatment of cancers
US7378503B2 (en)	2003-04-02	2008-05-27	Hoffmann-La Roche Inc.	Antibodies against insulin-like growth factor 1 receptor and uses thereof
DE602004029581D1 (de) *	2003-08-13	2010-11-25	Pfizer Prod Inc	Modifizierte humane igf-1r antikörper

2004
- 2004-08-03 DE DE602004029581T patent/DE602004029581D1/de not_active Expired - Lifetime
- 2004-08-03 DK DK04744197.7T patent/DK1656391T3/da active
- 2004-08-03 AT AT04744197T patent/ATE484525T1/de active
- 2004-08-03 BR BRPI0413466-4A patent/BRPI0413466A/pt not_active IP Right Cessation
- 2004-08-03 EP EP04744197A patent/EP1656391B1/en not_active Expired - Lifetime
- 2004-08-03 WO PCT/IB2004/002555 patent/WO2005016967A2/en not_active Ceased
- 2004-08-03 CN CN2004800230991A patent/CN1835975B/zh not_active Expired - Fee Related
- 2004-08-03 MX MXPA06001634A patent/MXPA06001634A/es unknown
- 2004-08-03 PL PL04744197T patent/PL1656391T3/pl unknown
- 2004-08-03 EA EA200600234A patent/EA200600234A1/ru unknown
- 2004-08-03 CA CA002535071A patent/CA2535071A1/en not_active Abandoned
- 2004-08-03 PT PT04744197T patent/PT1656391E/pt unknown
- 2004-08-03 RS YUP-2006/0099A patent/RS20060099A/sr unknown
- 2004-08-03 AU AU2004265152A patent/AU2004265152A1/en not_active Abandoned
- 2004-08-03 ES ES04744197T patent/ES2351395T3/es not_active Expired - Lifetime
- 2004-08-03 KR KR1020067002957A patent/KR100825156B1/ko not_active Expired - Fee Related
- 2004-08-03 AP AP2006003510A patent/AP2006003510A0/xx unknown
- 2004-08-03 OA OA1200600046A patent/OA13234A/en unknown
- 2004-08-03 JP JP2006523070A patent/JP4638870B2/ja not_active Expired - Fee Related
- 2004-08-03 UA UAA200601349A patent/UA85058C2/ru unknown
- 2004-08-09 PE PE2004000773A patent/PE20050339A1/es not_active Application Discontinuation
- 2004-08-10 CL CL200402035A patent/CL2004002035A1/es unknown
- 2004-08-11 AR ARP040102870A patent/AR045247A1/es active IP Right Grant
- 2004-08-11 UY UY28464A patent/UY28464A1/es not_active Application Discontinuation
- 2004-08-12 TW TW093124269A patent/TWI294915B/zh not_active IP Right Cessation
- 2004-08-12 US US10/917,073 patent/US7371378B2/en not_active Expired - Fee Related
- 2004-08-12 PA PA20048608801A patent/PA8608801A1/es unknown
- 2004-08-12 GT GT200400158A patent/GT200400158A/es unknown
- 2004-08-12 NL NL1026829A patent/NL1026829C2/nl not_active IP Right Cessation
2006
- 2006-01-19 IL IL173273A patent/IL173273A/en not_active IP Right Cessation
- 2006-01-26 IS IS8266A patent/IS8266A/is unknown
- 2006-02-02 NO NO20060542A patent/NO20060542L/no not_active Application Discontinuation
- 2006-02-10 EC EC2006006359A patent/ECSP066359A/es unknown
- 2006-02-10 ZA ZA200601231A patent/ZA200601231B/en unknown
- 2006-02-13 TN TNP2006000050A patent/TNSN06050A1/fr unknown
- 2006-02-13 CR CR8233A patent/CR8233A/es not_active Application Discontinuation
- 2006-02-13 MA MA28790A patent/MA27988A1/fr unknown
2008
- 2008-03-03 US US12/041,341 patent/US7575746B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
NL1026829C2 (nl)	2005-07-05
KR100825156B1 (ko)	2008-04-24
DE602004029581D1 (de)	2010-11-25
DK1656391T3 (da)	2011-01-03
EP1656391A2 (en)	2006-05-17
TNSN06050A1 (fr)	2007-10-03
ES2351395T3 (es)	2011-02-04
NL1026829A1 (nl)	2005-02-15
KR20060035796A (ko)	2006-04-26
MA27988A1 (fr)	2006-07-03
CN1835975A (zh)	2006-09-20
AR045247A1 (es)	2005-10-19
US20050069539A1 (en)	2005-03-31
GT200400158A (es)	2005-07-22
PT1656391E (pt)	2010-12-06
NO20060542L (no)	2006-05-03
PL1656391T3 (pl)	2011-03-31
MXPA06001634A (es)	2006-04-28
WO2005016967A2 (en)	2005-02-24
CR8233A (es)	2007-01-18
WO2005016967A3 (en)	2005-04-14
PE20050339A1 (es)	2005-05-17
IL173273A (en)	2011-10-31
US20080181891A1 (en)	2008-07-31
EA200600234A1 (ru)	2006-08-25
AP2006003510A0 (en)	2006-02-28
ATE484525T1 (de)	2010-10-15
BRPI0413466A (pt)	2006-10-17
UY28464A1 (es)	2005-03-31
CL2004002035A1 (es)	2005-06-03
AU2004265152A1 (en)	2005-02-24
PA8608801A1 (es)	2005-03-03
TW200516145A (en)	2005-05-16
UA85058C2 (ru)	2008-12-25
RS20060099A (sr)	2008-08-07
JP2007527705A (ja)	2007-10-04
OA13234A (en)	2006-12-13
EP1656391B1 (en)	2010-10-13
JP4638870B2 (ja)	2011-02-23
US7575746B2 (en)	2009-08-18
US7371378B2 (en)	2008-05-13
CN1835975B (zh)	2012-11-21
TWI294915B (en)	2008-03-21
IL173273A0 (en)	2006-06-11
ECSP066359A (es)	2006-10-31
CA2535071A1 (en)	2005-02-24
ZA200601231B (en)	2007-05-30

Publication	Publication Date	Title
IS8266A (is)	2006-01-26	Breytt mennsk IGF-1R mótefni
DE602004026768D1 (de)	2010-06-02	Therapeutische anti-igfr1-antikörper-kombinationen
DK1599504T3 (da)	2015-03-09	Modificeret antistof
NO20044347L (no)	2004-12-13	Anti-alfavbeta6-antistoff
EP1616881A4 (en)	2008-08-27	ANTI-MPL ANTIBODY
DE602004022855D1 (de)	2009-10-08	Interleukin-10-antikörper
NO20071430L (no)	2007-05-15	Anti-OX4OL antistoffer
CY2016035I1 (el)	2017-09-13	Θεραπευτικη χρηση αντισωματων anti-cs1
PL2177537T3 (pl)	2012-06-29	Przeciwciała przeciw MadCAM
NO2016001I1 (no)	2016-01-26	Trastuzumab emtansin
ATE549033T1 (de)	2012-03-15	Therapeutischer menschlicher monoklonaler anti-il-1r1-antikörper
DE502004003292D1 (de)	2007-05-03	Flugzeug
EP1765396A4 (en)	2008-07-02	ANTIBODY
DE502004011106D1 (de)	2010-06-10	6-arylmethyl-substituierte pyrazolopyrimidine
EP1598368A4 (en)	2007-07-25	ANTI-PCI neutralizing ANTIBODY
DE502004012209D1 (de)	2011-03-31	Einparkhilfe
DK1809660T3 (da)	2014-10-20	Thymus-specifikt protein
PT1678290T (pt)	2017-10-16	Resumo
EP1646401A4 (en)	2007-07-18	SPECIFIC HUMAN ANTIBODIES
DE602004023341D1 (de)	2009-11-12	Chronograph
NO20053512D0 (no)	2005-07-18	IL-8-liknende proteiner
FR2853701B1 (fr)	2006-03-03	Electrovanne
SI1656391T1 (sl)	2010-12-31	Modificirana humana IGF-1R protitelesa
DK1494693T3 (da)	2011-01-17	Cripto-specifikke antistoffer
NO20052608D0 (no)	2005-05-31	Midkinlignende protein